Meeting
2019 ASCO Annual Meeting
A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors.
Authors
Jason Alan Chesney
James Graham Brown Cancer Center, University of Louisville, Louisville, KY
Jason Alan Chesney , Jose Lutzky , Sajeve Samuel Thomas , Jorge J. Nieva , Eva Munoz Couselo , Juan Martin-Liberal , Juan Francisco Rodriguez-Moreno , Alex Cacovean , Huiling Li , Maria Fardis , Scott N. Gettinger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT03645928
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS2648)
DOI
10.1200/JCO.2019.37.15_suppl.TPS2648
Abstract #
TPS2648
Poster Bd #
290a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy.
First Author: Amod Sarnaik
Poster
2019 ASCO Annual Meeting
Lymphodepletion (LD), tumor-infiltrating lymphocytes (TIL) and high (HD-IL2) versus low-dose (LD-IL2) IL-2 followed by pembrolizumab (pembro) in patients (pts) with metastatic melanoma (MM).
First Author: Rodabe Navroze Amaria
Poster
2018 ASCO Annual Meeting
A phase 2 study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (TIL, LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab in patients with locally advanced or metastatic NSCLC.
First Author: Sylvia Mina Lee
Poster
2019 ASCO Annual Meeting
Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.
First Author: Amir A. Jazaeri